Sign in
4

Changes in Ownership

CORCEPT THERAPEUTICS INC Filed Acc 0001193125-26-330668

Chief Financial Officer sold 80,000 shares at an average $114.71 ($9,177,109)

  • Chief Financial Officer acquired 80,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Mokari Atabak · Chief Financial Officer

Table I: Non-derivative

14 lines
Date Transaction Shares Price Value Owned after D/I
2026-07-30 Exercise or conversion : show line 1 in the form 10b5-1 +80,000 $23.06 $1,844,800 96,130 D
2026-07-30 Sale : show line 2 in the form 10b5-1 −4,200 $105.54 $443,248 91,930 D
2026-07-30 Sale : show line 3 in the form 10b5-1 −8,956 $106.96 $957,892 82,974 D
2026-07-30 Sale : show line 4 in the form 10b5-1 −400 $108.46 $43,384 82,574 D
2026-07-30 Sale : show line 5 in the form 10b5-1 −2,202 $110.03 $242,282 80,372 D
2026-07-30 Sale : show line 6 in the form 10b5-1 −600 $110.95 $66,570 79,772 D
2026-07-30 Sale : show line 7 in the form 10b5-1 −4,700 $113.18 $531,941 75,072 D
2026-07-30 Sale : show line 8 in the form 10b5-1 −15,477 $114.96 $1,779,237 59,595 D
Open-market sales · 80,000 sh · avg $114.71 · $9,177,109

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-07-30 Exercise or conversion : show line 15 in the form 10b5-1 Stock option (right to buy) −80,000 95,833 D
Loading xslF345X06/ownership.xml…